Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market - GBI Research Reports

Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market

Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market - GBI Research Reports
Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market
Published Apr 01, 2011
108 pages — Published Apr 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research has released its pharmaceutical research, Gout Therapeutics Market to 2017 - Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market, which provides insights into gout therapeutics sales and price forecasts until 2017. The report also delves deep into global gout treatment usage patterns. Furthermore, the geographical distribution of the gout therapeutics market across key geographies (the US, the top five countries of Europe, and Japan) is also provided in the report. The report also provides insights into the gout therapeutics R&D pipeline and the promising future blockbusters by 2017. The report provides an in-depth analysis of acute and chronic gout. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also covers the profiles of major biopharmaceutical companies in this therapeutics segment. Finally, analysis of mergers and acquisitions, and licensing agreements involving gout therapeutics, is also provided.

GBI Research analysis showed that the global gout therapeutics market was estimated at $542.6m in 2010, with a year-on-year growth rate of 7% between 2002 and 2010. The gout therapeutics market is expected to shift towards biologics that are more efficient and safe compared to conventional therapies. GBI Research forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of approximately 16.3% between 2010 and 2017, to record a sales value of approximately $1,561.3m. The gout therapeutics market had only generics until the launch of Colcrys (colchicine) and TMX 67 (febuxostat) in 2009 and 2010 respectively. In-depth analysis of the report is based on proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of experts.

Scope

The report covers -
- Data and analysis on the gout therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the gout therapeutics market from 2002 to 2010, with forecasts to 2017.
- In-depth analysis of the acute and chronic gout therapeutics market.
- Market data on geographical landscape and therapeutic landscape including market size, annual cost of therapy, revenues and treatment usage patterns such as diseased population, treatment seeking population, diagnosed population and prescription population.
- Key drivers and barriers that have created a significant impact on the market.
- Profiles of the major biopharmaceutical markets in the gout therapeutics segment. The key companies studied in this report are Takeda Pharmaceutical Company, Savient Pharmaceuticals, Novartis, Regeneron Pharmaceuticals and Teijin Pharma.
- Key M&A activities and Licensing Agreements, that have taken place between 2004 and 2010 in the gout therapeutics market.

Reasons to buy

The report will aid business development and marketing executives strategizing their product launches -
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

  
Source:
Document ID
GBIHC099MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents36
  List of Tables52
  List of Figures72
Gout Therapeutics Market: Introduction91
  GBI Research Report Guidance91
Gout Therapeutics Market: Market Overview1011
  Introduction101
    Disease Overview101
      Progression Stages101
      Epidemiology101
      Symptoms101
      Diagnosis111
      Treatment111
    Global Market Overview121
  Revenue Forecasts for the Global Gout Therapeutics Market121
    Revenue122
    Annual Cost of Treatment (ACT)141
    Treatment Usage Patterns152
      Diseased Population171
      Treatment Seeking Population181
      Diagnosed Population191
      Prescription Population201
Gout Therapeutics Market: Geographic Landscape2136
  Revenue Analysis by Geography212
  The US231
    Revenue231
    Annual Cost of Treatment (ACT)241
    Treatment Usage Patterns252
      Diseased Population271
      Treatment Seeking Population281
      Diagnosed Population291
      Prescription Population301
  Top Five Countries of Europe311
    Revenue311
    Annual Cost of Treatment (ACT)321
    Treatment Usage Patterns332
      Diseased Population351
      Treatment Seeking Population361
      Diagnosed Population371
      Prescription Population381
    The UK391
      Revenue391
      Prescription Population401
    Germany411
      Revenue411
      Prescription Population421
    France431
      Revenue431
      Prescription Population441
    Italy451
      Revenue451
      Prescription Population461
    Spain471
      Revenue471
      Prescription Population481
  Japan491
    Revenue491
    Annual Cost of Treatment (ACT)501
    Treatment Usage Patterns512
      Diseased Population531
      Treatment Seeking Population541
      Diagnosed Population551
      Prescription Population561
Gout Therapeutics Market: Therapeutic Landscape5728
  Gout Therapeutics Market for Acute Gout571
    Introduction571
    Revenue572
    Revenue Analysis by Geography592
    Annual Cost of Treatment611
    Annual Cost of Treatment by Geography622
    Treatment Usage Patterns642
      Disease Population661
      Treatment Seeking Population671
      Diagnosed Population681
      Prescription Population691
  Gout Therapeutics Market for Chronic Gout701
    Introduction701
    Revenue702
    Revenue Analysis by Geography722
    Annual Cost of Treatment741
    Annual Cost of Treatment by Geography752
    Treatment Usage Patterns772
      Diseased Population791
      Treatment Seeking Population801
      Diagnosed Population811
      Prescription Population821
  Drivers and Barriers to the Gout Therapeutics Market831
    Drivers to the Gout Therapeutics Market831
      Expected Launch of New Drugs will Drive the Gout Therapeutics Market831
      Limited Number of Approved Therapies will Create Concentrated Patient Pools831
      Increasing Prevalence and Diagnosis will Drive the Gout Therapeutics Market831
    Barriers to the Gout Therapeutics Market841
      Lower Treatment Seeking Rate Could Prevent the Gout Therapeutics Market from Achieving Higher Growth841
      Low Patient Affordability for Biologics could Affect the Growth in the Future841
Gout Therapeutics Market: Product Pipeline Analysis854
  Introduction851
  Research and Development Pipeline851
    Overview851
    Pipeline by Clinical Phases of Development861
      Gout Therapeutics Discovery Product Pipeline861
      Gout Therapeutics Preclinical Product Pipeline861
      Gout Therapeutics Investigational New Drug (IND) Filed861
      Gout Therapeutics Phase I Product Pipeline861
      Gout Therapeutics Phase II Product Pipeline871
      Gout Therapeutics Phase III Product Pipeline871
  Profiles of Promising Drugs in the Gout Therapeutics Market881
    ACZ885881
      Overview881
      Mechanism of Action881
    Arcalyst881
      Overview881
      Mechanism of Action881
Gout Therapeutics Market: Company Profiles895
  Takeda Pharmaceutical Company Limited891
    Company Overview891
    SWOT Analysis891
  Savient Pharmaceuticals, Inc.901
    Company Overview901
    SWOT Analysis901
  Novartis AG911
    Company Overview911
    SWOT Analysis911
  Regeneron Pharmaceuticals, Inc.921
    Company Overview921
    SWOT Analysis921
  Teijin Pharma Limited931
    Company Overview931
    SWOT Analysis931
Gout Therapeutics Market: Strategic Consolidations949
  Overview941
  Mergers and Acquisitions951
    Major M&A Deals (2004-2010)951
    Deal Summary961
      Hi-Tech Pharmacal Acquires Licensing Rights of Naprelan from Stat-Trade961
      BioPhausia Acquires Pharmaceutical Products Portfolio from AstraZeneca961
      Polaris Acquires Intellectual Property Rights of Uricase-PEG 20 from Phoenix Pharmacologics961
      Strides Arcolab Acquires Drug Houses of Australia from Haw Par Healthcare961
      Hi-Tech Pharmacal and Stat-Trade Sell Rights of Naprelan to Victory Pharma961
      EnzymeRx Acquires Uricase-PEG 20 from Polaris Pharmaceuticals961
      Is Private Equity Acquires 17% Stake in Frik Ilac971
      3SBio Acquires Rights of Pegsiticase from EnzymeRx971
      Norgine Acquires 12.6% Stake in ProStrakan971
    Deals by Deal Value971
    Deals by Geography981
    Deals by Type991
  Licensing Agreements1001
    Major Licensing Deals1001
    Deal Summary1001
      Teijin Pharma Enters into Licensing Agreement with Astellas Pharma Taiwan1001
      Teijin Pharma Enters into Licensing Agreement with Menarini1001
      Menarini Enters into Licensing Agreement with Ipsen1001
      FAES Farma Enters into Licensing Agreement with Merck Sharp &Dohme1011
      Teijin Pharma Enters into an Agreement with Astellas Pharma1011
      XOMA Enters into Licensing Agreement with Les Laboratoires Servier for XOMA 0521011
    Deals by Geography1021
Gout Therapeutics Market: Appendix1036
  Market Definitions1031
  Abbreviations1031
  Research Methodology1045
    Coverage1041
    Primary Research1051
    Forecasts1051
      Epidemiology-based Forecasting1053
    Expert Panel Validation1081
  Contact Us1081
  Disclaimer1081
  Sources1081

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market" Apr 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Gout-Therapeutics-Market-to-2017-Entry-of-Novel-Therapies-such-as-Krystexxa-Uloric-Adenuric-and-Colcrys-to-Drive-Market-2115-188>
  
APA:
GBI Research Reports. (2011). Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market Apr 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Gout-Therapeutics-Market-to-2017-Entry-of-Novel-Therapies-such-as-Krystexxa-Uloric-Adenuric-and-Colcrys-to-Drive-Market-2115-188>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.